Soluble ST2 and Galectin-3 in heart failure

Clinics in Laboratory Medicine

Volumn 34, Issue 1, 2014, Pages 87-97

  Shah, Ravi V ^a   Januzzi, James L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Biomarkers; Cardiac markers; Laboratory medicine

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; INTERLEUKIN 1 RECEPTOR; MEMBRANE PROTEIN; PROTEIN ST2; UNCLASSIFIED DRUG;

ACUTE HEART FAILURE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HUMAN; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW;

BIOMARKERS; CARDIAC MARKERS; LABORATORY MEDICINE;

BIOLOGICAL MARKERS; EXTRACELLULAR MATRIX; GALECTIN 3; HEART FAILURE; HUMANS; PROGNOSIS; RECEPTORS, CELL SURFACE;

EID: 84895148258     PISSN: 02722712     EISSN: 15579832     Source Type: Journal    
DOI: 10.1016/j.cll.2013.11.009     Document Type: Review

References (49)

1. Januzzi J.L. Natriuretic peptides as biomarkers in heart failure. JInvestig Med 2013, 61:950-955.
2. Weinberg E., Shimpo M., De Keulenaer G., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002, 106:2961-2966.
3. Iwahana H., Yanagisawa K., Ito-Kosaka A., et al. Different promoter usage and multiple transcription initiation sites of the interleukin-1 receptor-related human ST2 gene in UT-7 and TM12 cells. Eur J Biochem 1999, 264:397-406.
4. Seki K., Sanada S., Kudinova A.Y., et al. Interleukin-33 prevents apoptosis and improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail 2009, 2:684-691.
5. Sanada S., Hakuno D., Higgins L.J., et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. JClin Invest 2007, 117:1538-1549.
6. Bartunek J., Delrue L., Van Durme F., et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. JAm Coll Cardiol 2008, 52:2166-2174.
7. Dieplinger B., Januzzi K., Steinmair M., et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma - the Presage ST2 assay. Clin Chim Acta 2009, 409:33-40.
8. Coglianese E.E., Larson M.G., Vasan R.S., et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 2012, 58:1673-1681.
9. Wang T.J., Wollert K.C., Larson M.G., et al. Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study. Circulation 2012, 126:1596-1604.
10. Henry-Okafor Q., Collins S.P., Jenkins C.A., et al. Soluble ST2 as a diagnostic and prognostic marker for acute heart failure syndromes. Open Biomark J 2012, 2012:1-8.
11. Januzzi J.L., Peacock W.F., Maisel A.S., et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. JAm Coll Cardiol 2007, 50:607-613.
12. Martinez-Rumayor A., Camargo C.A., Green S.M., et al. Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease. Am J Clin Pathol 2008, 130:578-584.
13. Lassus J., Gayat E., Mueller C., et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013, 168:2186-2194.
14. Rehman S., Mueller T., Januzzi J.L. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. JAm Coll Cardiol 2008, 52:1458-1465.
15. Manzano-Fernandez S., Mueller T., Pascual-Figal D., et al. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol 2011, 107:259-267.
16. Shah R.V., Chen-Tournoux A.A., Picard M.H., et al. Serum levels of the interleukin-1receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea. Circ Heart Fail 2009, 2:311-319.
17. Pascual-Figal D.A., Manzano-Fernandez S., Boronat M., et al. Soluble ST2, high-sensitivity troponin T- and N-terminal pro-B-type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure. Eur J Heart Fail 2011, 13:718-725.
18. Mueller T., Dieplinger B., Gegenhuber A., et al. Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. Clin Chem 2008, 54:752-756.
19. Manzano-Fernandez S., Januzzi J.L., Pastor-Perez F.J., et al. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 2012, 122:158-166.
20. Boisot S., Beede J., Isakson S., et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. JCard Fail 2008, 14:732-738.
21. Zilinski J.L., Shah R.V., Gaggin H.K., et al. Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy. Crit Care 2012, 16:R135.
22. Daniels L.B., Clopton P., Iqbal N., et al. Association of ST2 levels with cardiac structure and function and mortality in outpatients. Am Heart J 2010, 160:721-728.
23. Ky B., French B., McCloskey K., et al. High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 2011, 4:180-187.
24. Bayes-Genis A., Pascual-Figal D., Januzzi J.L., et al. Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. Rev Esp Cardiol 2010, 63:1171-1178.
25. Broch K., Ueland T., Nymo S.H., et al. Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology. Eur J Heart Fail 2012, 14:268-277.
26. Bayes-Genis A., de Antonio M., Galan A., et al. Combined use of high-sensitivity ST2 and NTproBNP to improve the prediction of death in heart failure. Eur J Heart Fail 2012, 14:32-38.
27. Pascual-Figal D.A., Ordonez-Llanos J., Tornel P.L., et al. Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. JAm Coll Cardiol 2009, 54:2174-2179.
28. Kohli P., Bonaca M.P., Kakkar R., et al. Role of ST2 in non-ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem 2012, 58:257-266.
29. Sabatine M.S., Morrow D.A., Higgins L.J., et al. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation 2008, 117:1936-1944.
30. Weir R.A., Miller A.M., Murphy G.E., et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. JAm Coll Cardiol 2010, 55:243-250.
31. Sharma U.C., Pokharel S., van Brakel T.J., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
32. Calvier L., Miana M., Reboul P., et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 2013, 33:67-75.
33. Yu L., Ruifrok W.P., Meissner M., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail 2013, 6:107-117.
34. Gruson D., Ko G. Galectins testing: new promises for the diagnosis and risk stratification of chronic diseases?. Clin Biochem 2012, 45:719-726.
35. Ho J.E., Liu C., Lyass A., et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. JAm Coll Cardiol 2012, 60:1249-1256.
36. van Kimmenade R.R., Januzzi J.L., Ellinor P.T., et al. Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. JAm Coll Cardiol 2006, 48:1217-1224.
37. Shah R.V., Chen-Tournoux A.A., Picard M.H., et al. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010, 12:826-832.
38. Lin Y.H., Lin L.Y., Wu Y.W., et al. The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients. Clin Chim Acta 2009, 409:96-99.
39. van der Velde A.R., Gullestad L., Ueland T., et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ Heart Fail 2013, 6:219-226.
40. Anand I.S., Rector T.S., Kuskowski M., et al. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013, 15:511-518.
41. Gullestad L., Ueland T., Kjekshus J., et al. The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Am Heart J 2012, 164:878-883.
42. Lok D.J., Van Der Meer P., de la Porte P.W., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 2010, 99:323-328.
43. Felker G.M., Fiuzat M., Shaw L.K., et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ Heart Fail 2012, 5:72-78.
44. Motiwala S.R., Szymonifka J., Belcher A., et al. Serial measurement of galectin-3 in patients with chronic heart failure: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Eur J Heart Fail 2013, 15:1157-1163.
45. Lok D.J., Lok S.I., Bruggink-Andre de la Porte P.W., et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin Res Cardiol 2013, 102:103-110.
46. Tang W.H., Shrestha K., Shao Z., et al. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am J Cardiol 2011, 108:385-390.
47. de Boer R.A., Lok D.J., Jaarsma T., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 2011, 43:60-68.
48. Lopez-Andres N., Rossignol P., Iraqi W., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012, 14:74-81.
49. Erkilet G., Ozpeker C., Bothig D., et al. The biomarker plasma galectin-3 in advanced heart failure and survival with mechanical circulatory support devices. JHeart Lung Transplant 2013, 32:221-230.